Study Protocol

**Study Title:**

**Study Acronym:**

**Phase of Development:**

**Protocol Number:**

**Protocol Version and Date:**

**EudraCT Registry Number:**

**ClinicTrials.gov Registry Number:**

**Indication:**

**Investigational product**:

**Sponsor:**

**Coordinating/Principal Investigator:**

The information contained in this document is the property of the Sponsor/Coordinating Investigator and may not be reproduced, published or disclosed to others without written authorization of the Sponsor/Coordinating Investigator.

# PROTOCOL SIGNATURE PAGE

**Protocol Version and date:**

**Protocol Title:**

**Sponsor:**

**Principal Investigator:**

I agree:

* to assume responsibility for the proper conduct of this study
* to conduct the study in compliance with this protocol and any future amendments
* not to implement any deviations from or changes to the protocol without prior review and written approval from the Ethics Committee, except where necessary to eliminate an immediate hazard to the subjects, or for administrative aspects of the study (where permitted by all applicable regulatory requirements)
* that I am thoroughly familiar with the appropriate use of the investigational drug, as described in this protocol
* to ensure that all persons assisting me with the study are adequately informed about the investigational drug and their study-related duties and functions as described in the protocol
* that I am aware of and will comply with the current good clinical practice (GCP) guidelines and ethical principles outlined in the Declaration of Helsinki
* to conduct the study in accordance with all applicable laws and regulations

Printed name Signature Date

# Table of Contents

[PROTOCOL SIGNATURE PAGE 1](#_Toc494364767)

[1. Table of Contents 2](#_Toc494364768)

[2. Trial Registration/Protocol Summary 5](#_Toc494364769)

[3. Protocol Version History 6](#_Toc494364770)

[4. Sponsor/Coordinating Investigator Information 6](#_Toc494364771)

[5. List of Abbreviations 6](#_Toc494364772)

[6. Introduction 6](#_Toc494364773)

[6.1 Overview of Disease Pathogenesis 6](#_Toc494364774)

[6.2 Epidemiology 6](#_Toc494364775)

[6.3 Current Treatments 6](#_Toc494364776)

[6.4 Study Rationale and Purpose 6](#_Toc494364777)

[6.5 Rationale for Study Design 6](#_Toc494364778)

[6.6 Rationale for Dose and Regimen/Schedule Selection 6](#_Toc494364779)

[7. Study Schematic and Schedule of Activities 7](#_Toc494364780)

[7.1 Study Schematic 7](#_Toc494364781)

[7.2 Study Activities 7](#_Toc494364782)

[8. Study Objectives and endpoints 7](#_Toc494364783)

[8.1 Primary Objective 7](#_Toc494364784)

[8.2 Secondary Objectives 7](#_Toc494364785)

[8.3 Endpoints 7](#_Toc494364786)

[9. Investigational Plan 7](#_Toc494364787)

[9.1 Overall Study Design 7](#_Toc494364788)

[9.2 Study Duration for Subjects 7](#_Toc494364789)

[*9.2.1 Screening* 7](#_Toc494364790)

[*9.2.2 Treatment Period* 7](#_Toc494364791)

[*9.2.3 Unscheduled Visit(s)* 7](#_Toc494364792)

[*9.2.4 Early Study Termination* 7](#_Toc494364793)

[*9.2.5 End of Study* 7](#_Toc494364794)

[10. Selection of Subjects 7](#_Toc494364795)

[10.1 Selection of Study Population 7](#_Toc494364796)

[10.2 Inclusion Criteria 7](#_Toc494364797)

[10.3 Exclusion Criteria 7](#_Toc494364798)

[10.4 Contraception/Pregnancy Avoidance 7](#_Toc494364799)

[11. Screening and Randomization 7](#_Toc494364800)

[11.1 Screening and Enrollment 7](#_Toc494364801)

[11.2 Randomization 7](#_Toc494364802)

[11.3 Blinding Procedures 7](#_Toc494364803)

[12. Interventions/Treatment 8](#_Toc494364804)

[12.1 Treatments Administered 8](#_Toc494364805)

[12.2 Product Characteristics 8](#_Toc494364806)

[12.3 Randomization and Stratification 8](#_Toc494364807)

[12.4 Direction of Administration 8](#_Toc494364808)

[12.5 Dosing Regimen11.6 Dose Modifications 8](#_Toc494364809)

[*12.5.1 Dose Modifications and Dose Delay* 8](#_Toc494364810)

[*12.5.2 Treatment Interruption and Treatment Discontinuation* 8](#_Toc494364811)

[12.7 Treatment Compliance 8](#_Toc494364812)

[12.8 Study Drug Accountability 8](#_Toc494364813)

[12.9 Storage, Packaging and Labeling 8](#_Toc494364814)

[12.10 Blinding 8](#_Toc494364815)

[12.11 Prior and Concomitant Medication 8](#_Toc494364816)

[12.12 Non-Drug Therapies 8](#_Toc494364817)

[12.13 Prohibited Medication 8](#_Toc494364818)

[12.14 Prohibited Procedures 8](#_Toc494364819)

[12.14 Other Interactions 8](#_Toc494364820)

[12.16 Study Disposal and Destruction 8](#_Toc494364821)

[12.17 Known Undesirable Effects of Study Drug 8](#_Toc494364822)

[13. Study Assessments and Procedures 8](#_Toc494364823)

[13.1 Study Assessments 8](#_Toc494364824)

[*13.1.1* Screening 8](#_Toc494364825)

[*13.1.2 Baseline* 8](#_Toc494364826)

[*13.1.3 Run-In* 8](#_Toc494364827)

[*13.1.4 Treatment Period* 8](#_Toc494364828)

[*13.1.5 Follow-Up* 8](#_Toc494364829)

[*13.1.6 End of Study* 8](#_Toc494364830)

[*13.1.7 Re-screening* 9](#_Toc494364831)

[*13.1.8 Early Termination* 9](#_Toc494364832)

[*13.1.9 Unscheduled Visits* 9](#_Toc494364833)

[13.2 Assessment Types 9](#_Toc494364834)

[*13.2.1 Efficacy Assessment* 9](#_Toc494364835)

[*13.2.2 Safety and Tolerability Assessments* 9](#_Toc494364836)

[*13.2.3 Physical Examination* 9](#_Toc494364837)

[*13.2.4 Vital Signs, Height, Weight…* 9](#_Toc494364838)

[*13.2.5 ECG….* 9](#_Toc494364839)

[*13.2.6 Laboratory Evaluation* 9](#_Toc494364840)

[14. Safety Monitoring and Reporting 9](#_Toc494364841)

[14.1 Adverse Events 9](#_Toc494364842)

[*14.1.1 Definitions and Reporting* 9](#_Toc494364843)

[*14.1.2 Reporting Period* 9](#_Toc494364844)

[*14.1.3 Laboratories Test Abnormalities* 9](#_Toc494364845)

[14.2 Serious Adverse Events 9](#_Toc494364846)

[*14.2.1 Definitions* 9](#_Toc494364847)

[*14.2.2 Immediate Reporting* 9](#_Toc494364848)

[14.3 Suspected Unexpected Serious Adverse Events (SUSAR) 9](#_Toc494364849)

[*14.3.1 Definitions* 9](#_Toc494364850)

[*14.3.2 Reporting* 9](#_Toc494364851)

[14.4 Other safety data requiring an immediate declaration 10](#_Toc494364852)

[14.5 Procedures for Handling Special Situations 10](#_Toc494364853)

[*14.5.1 Pregnancy* 10](#_Toc494364854)

[*14.2.2 Overdose Management* 10](#_Toc494364855)

[14.6 Annual Safety Report 10](#_Toc494364856)

[15. Data Collection and Management 10](#_Toc494364857)

[15.1 Monitoring 10](#_Toc494364858)

[*15.1.1 Composition of data monitoring committee* 10](#_Toc494364859)

[*15.1.2 Interim analysis* 10](#_Toc494364860)

[15.2 Data Collection 10](#_Toc494364861)

[15.3 Database Management and Quality Control 10](#_Toc494364862)

[15.4 Statistical Considerations and Data Analysis 10](#_Toc494364863)

[16. Ethical Considerations 10](#_Toc494364864)

[16.1 Ethical conduct of the study 10](#_Toc494364865)

[*16.1.1 Declaration of Helsinki* 10](#_Toc494364866)

[*16.1.2 Ethics Committee* 10](#_Toc494364867)

[16.2 Informed Consent 10](#_Toc494364868)

[16.3 Patient and Study Data Protection 10](#_Toc494364869)

[16.4 Subject Identification 10](#_Toc494364870)

[16.5 Conflict of Interest 10](#_Toc494364871)

[17. Finance and Insurance 11](#_Toc494364872)

[18. Reporting and Dissemination 11](#_Toc494364873)

[19. Conflict of interest statement 11](#_Toc494364874)

[20. Tables and Figures 11](#_Toc494364875)

[21. References 11](#_Toc494364876)

# Trial Registration/Protocol Summary

|  |
| --- |
| **Information** |
| EudraCT number:Date of registration: |  |
| Clinical Trial Authorization (CTA) from FAMHP (FAGG)Date of approval: |  |
| ClinicalTrials.gov: |  |
| Official Title: |  |
| Study Phase/Type: |  |
| Condition: |  |
| Objectives: |  |
| Investigational Product: |  |
| Interventions: |  |
| Endpoints: |  |
| Study population: |  |
| Number of patients: |  |
| Overview of study design: |  |
| Statistical Considerations: |  |
| Sponsor: |  |
| Country(ies) of Recruitment: |  |
| Inclusion Criteria: |  |
| Exclusion Criteria: |  |
| Date of first enrolment: |  |
| Target sample size: |  |

# Protocol Version History

|  |  |  |
| --- | --- | --- |
| **Version No.** | **Approval Date Lead EC** | **Release Date** |
|  |  |  |
|  |  |  |
|  |  |  |

# Sponsor/Coordinating Investigator Information

Coordinating Investigator

Sponsor

Principal Investigator

Co-investigators

Additional co-researchers

Statistician

Laboratory (ies)

Pharmacy

Study Coordinator

Study sites and co-investigators

# List of Abbreviations

# Introduction

## 6.1 Overview of Disease Pathogenesis

## 6.2 Epidemiology

## 6.3 Current Treatments

## 6.4 Study Rationale and Purpose

## 6.5 Rationale for Study Design

## 6.6 Rationale for Dose and Regimen/Schedule Selection

# Study Schematic and Schedule of Activities

## 7.1 Study Schematic

## 7.2 Study Activities

# Study Objectives and endpoints

## 8.1 Primary Objective

## 8.2 Secondary Objectives

## 8.3 Endpoints

# Investigational Plan

## 9.1 Overall Study Design

## 9.2 Study Duration for Subjects

### *9.2.1 Screening*

### *9.2.2 Treatment Period*

### *9.2.3 Unscheduled Visit(s)*

### *9.2.4 Early Study Termination*

### *9.2.5 End of Study*

# Selection of Subjects

## 10.1 Selection of Study Population

## 10.2 Inclusion Criteria

## 10.3 Exclusion Criteria

## 10.4 Contraception/Pregnancy Avoidance

# Screening and Randomization

## 11.1 Screening and Enrollment

## 11.2 Randomization

## 11.3 Blinding Procedures

# Interventions/Treatment

## 12.1 Treatments Administered

## 12.2 Product Characteristics

## 12.3 Randomization and Stratification

## 12.4 Direction of Administration

## 12.5 Dosing Regimen11.6 Dose Modifications

### *12.5.1 Dose Modifications and Dose Delay*

### *12.5.2 Treatment Interruption and Treatment Discontinuation*

## 12.7 Treatment Compliance

## 12.8 Study Drug Accountability

## 12.9 Storage, Packaging and Labeling

## 12.10 Blinding

## 12.11 Prior and Concomitant Medication

## 12.12 Non-Drug Therapies

## 12.13 Prohibited Medication

## 12.14 Prohibited Procedures

## 12.14 Other Interactions

## 12.16 Study Disposal and Destruction

## 12.17 Known Undesirable Effects of Study Drug

# Study Assessments and Procedures

## 13.1 Study Assessments

###  *13.1.1* Screening

### *13.1.2 Baseline*

### *13.1.3 Run-In*

### *13.1.4 Treatment Period*

### *13.1.5 Follow-Up*

### *13.1.6 End of Study*

### *13.1.7 Re-screening*

### *13.1.8 Early Termination*

### *13.1.9 Unscheduled Visits*

## 13.2 Assessment Types

### *13.2.1 Efficacy Assessment*

### *13.2.2 Safety and Tolerability Assessments*

### *13.2.3 Physical Examination*

### *13.2.4 Vital Signs, Height, Weight…*

### *13.2.5 ECG….*

### *13.2.6 Laboratory Evaluation*

#### 13.2.6.1 Clinical Chemistry

#### 13.2.6.2 Hematology

#### 13.2.6.4 Urine Analysis

#### 13.2.6.5 Pharmacokinetics….

# 14. Safety Monitoring and Reporting

## 14.1 Adverse Events

### *14.1.1 Definitions and Reporting*

### *14.1.2 Reporting Period*

### *14.1.3 Laboratories Test Abnormalities*

## 14.2 Serious Adverse Events

### *14.2.1 Definitions*

### *14.2.2 Immediate Reporting*

## 14.3 Suspected Unexpected Serious Adverse Events (SUSAR)

### *14.3.1 Definitions*

### *14.3.2 Reporting*

## 14.4 Other safety data requiring an immediate declaration

## 14.5 Procedures for Handling Special Situations

### *14.5.1 Pregnancy*

### *14.2.2 Overdose Management*

## 14.6 Annual Safety Report

# 15. Data Collection and Management

## 15.1 Monitoring

### *15.1.1 Composition of data monitoring committee*

### *15.1.2 Interim analysis*

## 15.2 Data Collection

## 15.3 Database Management and Quality Control

## 15.4 Statistical Considerations and Data Analysis

# 16. Ethical Considerations

## 16.1 Ethical conduct of the study

### *16.1.1 Declaration of Helsinki*

### *16.1.2 Ethics Committee*

## 16.2 Informed Consent

## 16.3 Patient and Study Data Protection

## 16.4 Subject Identification

## 16.5 Conflict of Interest

#

# 17. Finance and Insurance

# 18. Reporting and Dissemination

# 19. Conflict of interest statement

# 20. Tables and Figures

# 21. References